AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 10657819
Drug: Exercise group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise group (10 tuck jumps 3 times weekly, jumping, hopping, and skipping incorporated into twice weekly physical education classes)
Trial: 21808985
Drug: Intravenous thrombolysis
RxNorm normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous thrombolysis with alteplase (0.9 mg/kg)
Trial: 15620935
Drug: Collagen-gentamicin (260
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collagen-gentamicin (260 mg gentamicin) sponges applied within the sternotomy before wound closure
Trial: 17931240
Drug: Intravenous isoxazolyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous isoxazolyl penicillin alone
Trial: 17931240
Drug: Collagen-gentamicin (260
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collagen-gentamicin (260 mg gentamicin) sponges
Trial: 15925031
Drug: Clonidine (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (0.3 mg/day)
Trial: 15536640
Drug: Active placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active placebo (loratadine 10 mg/day)
Trial: 11907500
Drug: Finasteride, 1
RxNorm normalized name: Finasteride, 1 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finasteride, 1 mg/d
Trial: 2093381
Drug: Trimetazidine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimetazidine (60 mg per day)
Trial: 2093381
Drug: Nifedipine (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (40 mg per day)
Trial: 28187751
Drug: simeprevir 75
RxNorm normalized name: Simeprevir
DrugBank: Simeprevir (DB06290)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: simeprevir 75 mg once daily + TMC647055 450 mg once daily/ritonavir 30 mg once daily + ribavirin 1000-1200 mg/day (Panel 1)
Trial: 28187751
Drug: simeprevir 75
RxNorm normalized name: Simeprevir
DrugBank: Simeprevir (DB06290)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: simeprevir 75 mg once daily + TMC647055 450 mg once daily/ritonavir 30 mg once daily + ribavirin 1000-1200 mg/day (Panel 2-Arm 1)
Trial: 28187751
Drug: simeprevir 75
RxNorm normalized name: Simeprevir
DrugBank: Simeprevir (DB06290)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: simeprevir 75 mg + TMC647055 450 mg/ritonavir 30 mg without ribavirin (Panel 2-Arm 2)
Trial: 28187751
Drug: simeprevir 75
RxNorm normalized name: Simeprevir
DrugBank: Simeprevir (DB06290)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: simeprevir 75 mg + TMC647055 450 mg/ritonavir 30 mg + JNJ-56914845 30 mg once daily (Panel 4-Arm 1)
Trial: 28187751
Drug: simeprevir 75
RxNorm normalized name: Simeprevir
DrugBank: Simeprevir (DB06290)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: simeprevir 75 mg + TMC647055 450 mg/ritonavir 30 mg + JNJ-56914845 60 mg once daily (Panel 4-Arm 2)
Trial: 3060151
Drug: Metoclopramide (high-dose)
DrugBank: Metoclopramide (DB01233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metoclopramide (high-dose)
Trial: 31197894
Drug: Daylight PDT
RxNorm normalized name: calcium carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daylight PDT with curettage (standard treatment)
Trial: 26004075
Drug: Topical citicoline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical citicoline (OMK1®, Omikron Italia, 3 drops/day) over a 4-month period
Trial: 28239491
Drug: Beta-blocker monotherapy
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blocker monotherapy
Trial: 23084029
Drug: Combination Z
RxNorm normalized name: Z-160
DrugBank: Z-160 (DB12743)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination Z (oxygenated alcoholic beverage and oxygenated water)
Trial: 23084029
Drug: Combination X
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination X (normal alcoholic beverage and normal water)
Trial: 23084029
Drug: Combination Y
RxNorm normalized name: Neuropeptide Y
DrugBank: Neuropeptide Y (DB11788)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination Y (oxygenated alcoholic beverage and normal water)
Trial: 21784297
Drug: Medication switch
RxNorm normalized name: witch hazel Medicated Pad
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication switch (SSRI or venlafaxine) with cognitive-behavioral therapy
Trial: 22354934
Drug: Heparin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin plus a GPI
Trial: 21907540
Drug: Fluoxetine (SSRI)
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluoxetine (SSRI)
Trial: 8342757
Drug: Intermittent bolus
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent bolus injection (Group B, n = 10)
Trial: 8342757
Drug: Patient controlled
RxNorm normalized name: PATIENT CONTROLLED ANALGESIA VIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient controlled administration with continuous infusion (Group P, n = 10)
Trial: 1936347
Drug: Ultrasonic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasonic therapy
Trial: 9184268
Drug: Muscle relaxant
RxNorm normalized name: MUSCLE RELAXANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Muscle relaxant drugs
Trial: 20441723
Drug: Citalopram (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (20 mg to 50 mg/d)
Trial: 18583190
Drug: Preoperative chemoradiation
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative chemoradiation (three cycles of cisplatin and etoposide, followed by twice-daily radiation with concurrent carboplatin and vindesine)
Trial: 8956204
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg oral formulation of melatonin
Trial: 1416895
Drug: sulbactam-ampicillin (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sulbactam-ampicillin (4 doses of 3 g ampicillin and 1.5 g sulbactam i.v. every 6 h)
Trial: 1416895
Drug: clindamycin-amikacin (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: clindamycin-amikacin (4 doses of 600 mg clindamycin i.v. every 6 h and 2 doses of 500 mg amikacin i.v. every 12 h)
Trial: 3858547
Drug: Prostaglandin E2
RxNorm normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Prostaglandin E2 (PGE2) 3 mg/day orally for four days
Trial: 24378880
Drug: Group-based acceptance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group-based acceptance and commitment therapy (GACT)
Trial: 24378880
Drug: Recommended pharmacological
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recommended pharmacological treatment (RPT; pregabalin + duloxetine)
Trial: 19278084
Drug: Oscillating/rotating power
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oscillating/rotating power toothbrush (Oral-B Triumph Professional Care 9000)
Trial: 8904352
Drug: Dideuterated glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dideuterated glucose as tracer, with non-adapted tracer priming dose
Trial: 8904352
Drug: Dideuterated glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dideuterated glucose as tracer, with appropriately matched priming dose
Trial: 31373919
Drug: Antiretroviral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiretroviral treatment (ART) discontinuation
Trial: 28863364
Drug: PBdiet (42
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PBdiet (42 g various protein sources, n=19)
Trial: 28863364
Drug: CBdiet (high‐carbohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBdiet (high‐carbohydrate breakfast, 17 g protein from various sources, n=18)
Trial: 16157010
Drug: COX‐2 inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COX‐2 inhibitor therapy (Rofecoxib) 25 mg/day for 10 days before surgery
Trial: 12825134
Drug: UDCA at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UDCA at 600 mg/day plus bezafibrate at 400 mg/day
Trial: 12825134
Drug: UDCA at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UDCA at 600 mg/day (control group)
Trial: 10971229
Drug: USA UDCA
RxNorm normalized name: UDCA
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: USA UDCA tablet
Trial: 10971229
Drug: Canadian UDCA
RxNorm normalized name: Canadian bluegrass pollen extract
DrugBank: Poa compressa pollen (DB10713)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canadian UDCA tablet
Trial: 10971229
Drug: North American
RxNorm normalized name: North American coral snake antivenin
DrugBank: Coral snake (micrurus fulvius) immune globulin antivenin (equine) (DB13883)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: North American tablets
Trial: 2223345
Drug: 10 ml
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml of 0.25% bupivacaine plain solution
Trial: 2223345
Drug: 20 ml
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 ml of 0.25% bupivacaine plain solution
Trial: 1458939
Drug: Dopamine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine infusion > 5 micrograms/kg/min for 4 hrs
Trial: 30892700
Drug: Neoadjuvant chemoendocrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemoendocrine therapy (NCET)
Trial: 27380504
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (α‐blocker, anti‐inflammatory agent, muscle relaxant)
Trial: 27380504
Drug: Combined extracorporeal
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined extracorporeal shock-wave therapy (ESWT) and triple therapy
Trial: 22351381
Drug: Lamotrigine 100
RxNorm normalized name: lamotrigine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamotrigine 100 mg/day
Trial: 20538187
Drug: NGX‐4010, a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NGX‐4010, a high‐concentration capsaicin patch (capsaicin 8%)
Trial: 14580927
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of inhaled salmeterol (50 microg) (T1)
Trial: 14580927
Drug: Regular treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular treatment with inhaled salmeterol (50 microg bid) for 1 week (T2)
Trial: 10544919
Drug: Oral lefradafiban
RxNorm normalized name: Lefradafiban
DrugBank: Lefradafiban (DB04863)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral lefradafiban (the oral prodrug of fradafiban)
Trial: 15215800
Drug: Noninvasive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Noninvasive treatment
Trial: 6194145
Drug: Acyclovir (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acyclovir (5 mg/kg)
Trial: 8695076
Drug: IV alfentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV alfentanil (ALF) 10 mcg/kg
Trial: 1514331
Drug: No spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No spray (Control)
Trial: 6476334
Drug: 1.0 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg/kg ketamine
Trial: 30927644
Drug: Antioxidant supplementation
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant supplementation with vitamin C (500 mg/d) and E (400 UI/d) for 15 days
Trial: 29991707
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of PgE1 and endothelin‐1 blocker (bosentan)
Trial: 25593496
Drug: BOACT group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BOACT group (240 mg bismuth subcitrate, 20 mg omeprazole, 1000 mg amoxicillin, 500 mg clarithromycin, 500 mg tinidazole)
Trial: 7522798
Drug: 127I-labeled peptides
RxNorm normalized name: PEPTIDE-T
DrugBank: Peptide-T (DB19279)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 127I-labeled peptides tested for their ability to displace 125I-T4 binding to thyroid hormone autoantibodies (THAA) in Graves' disease cases.
Trial: 7522798
Drug: 125I-labeled peptides
RxNorm normalized name: PEPTIDE-T
DrugBank: Peptide-T (DB19279)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125I-labeled peptides tested for direct binding to antibodies.
Trial: 3028892
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of L‐3H‐NA
Trial: 3028892
Drug: L‐3H‐noradrenaline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐3H‐noradrenaline infusion
Trial: 29224236
Drug: Primary treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary treatment
Trial: 23803895
Drug: 2:1 lipid:protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2:1 lipid:protein combination (L2P1)
Trial: 23803895
Drug: 1:2 lipid:protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1:2 lipid:protein combination (L1P2)
Trial: 17625308
Drug: Long-term infusion
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term infusion of gabexate (12 hours)
Trial: 17625308
Drug: Short-term infusion
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term infusion of gabexate (2.5 and 6.5 hours)
Trial: 17625308
Drug: Short-term administration
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term administration of ulinastatin (10 minutes)
Trial: 17625308
Drug: Long-term infusion
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term infusion of gabexate
Trial: 11421841
Drug: Ropivacaine, 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine, 2 mg x ml(‐1) with continuous infusion of 6 ml x h(‐1) and PCEA bolus doses of 2 ml
Trial: 11421841
Drug: Bupivacaine, 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine, 2 mg x ml(‐1) with continuous infusion of 6 ml x h(‐1) and PCEA bolus doses of 2 ml
Trial: 3126699
Drug: Magnesium hydroxide
RxNorm normalized name: Magnesium Hydroxide
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Magnesium hydroxide (25 ml daily)
Trial: 11072596
Drug: Oral chicken
RxNorm normalized name: Chicken
DrugBank: Chicken (DB10519)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral chicken type II collagen (CII) at 0.25 mg/day (n = 31)
Trial: 31241002
Drug: Placebo (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (10 g/day Maltodextrin)
Trial: 23144810
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D insufficiency (<30 ng/mL)
Trial: 23144810
Drug: Serum 25(OH)D
RxNorm normalized name: 1α,25(OH)2D3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum 25(OH)D concentrations categorized as <10, 10-20, 20-30, and ≥30 ng/mL
Trial: 15752880
Drug: Rectangular or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectangular or conformal fields with a dose of 66 Gy
Trial: 10436100
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (plasma homocyst(e)ine level < 7.3 micromol/L)
Trial: 21336804
Drug: Anti-platelet drugs
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-platelet drugs
Trial: 15088883
Drug: LDD (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDD (20 mg b.i.d.) + AFS
Trial: 11531834
Drug: Sirolimus 3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sirolimus 3.0 mg m(‐2) daily + cyclosporin 1.25 mg kg(‐1) daily
Trial: 11531834
Drug: Cyclosporin 5.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporin 5.0 mg kg(‐1) daily
Trial: 11531834
Drug: Cyclosporin 1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporin 1.25 mg kg(‐1) daily
Trial: 11531834
Drug: Sirolimus plus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sirolimus plus reduced‐dose cyclosporin
Trial: 31730369
Drug: Attentional Bias
RxNorm normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Attentional Bias Modification Therapy (ABMT)
Trial: 30246184
Drug: Non-occluding provisional
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-occluding provisional acrylic reinforced prosthesis within 24 h of implant placement
Trial: 16814131
Drug: Oral hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral hormone replacement therapy (HRT) with continuous oral conjugated equine estrogens (CEE; 0.625 mg/day) plus cyclic oral MPA (2.5 mg/day for 12 days) for 12 months
Trial: 12904807
Drug: Apomorphine sublingual
RxNorm normalized name: apomorphine Sublingual Film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apomorphine sublingual
Trial: 18190664
Drug: Methadone maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone maintenance treatment
Trial: 22683226
Drug: Controlled-release carbamazepine
RxNorm normalized name: carbamazepine Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-release carbamazepine
Trial: 29948233
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral treatment (CBT)
Trial: 10563033
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral treatment with Nicorette gum
Trial: 1812498
Drug: imipramine 75
RxNorm normalized name: trimipramine 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: imipramine 75 mg
Trial: 25280414
Drug: Polyunsaturated fatty
RxNorm normalized name: omega-3 polyunsaturated fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyunsaturated fatty acids (PUFA) intake as percentage of daily energy (median 5.3%)
Trial: 20075928
Drug: Candesartan therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan therapy for 6 months
Trial: 18503053
Drug: Granulocyte colony-stimulating
RxNorm normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granulocyte colony-stimulating factor (G-CSF) levels in follicular fluids
Trial: 27572327
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg triamcinolone hexacetonide (TH)
Trial: 27572327
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg dexamethasone (DEX)
Trial: 25202955
Drug: Ambroxol (1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambroxol (1,000 mg/d on the day of operation and on the first 3 postoperative days)
Trial: 11876581
Drug: Completion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Completion of full treatment
Trial: 10655905
Drug: Dexmedetomidine (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (0.6 ng ml‐1)
Trial: 10655905
Drug: Placebo (0.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0.0 ng ml‐1)
Trial: 19233534
Drug: 6% hydrogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6% hydrogen peroxide whitening strips used twice daily for 30 minutes over a 2-week period
Trial: 1837130
Drug: UW solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UW solution
Trial: 7678358
Drug: UW-mod solution
RxNorm normalized name: MOD-423 hGH analogue
DrugBank: Somatrogon (DB14960)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: UW-mod solution
Trial: 29614991
Drug: Complete administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complete administration of chemotherapy cycles
Trial: 29614991
Drug: Incomplete administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Incomplete administration of chemotherapy cycles
Trial: 31888732
Drug: Medication Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication Therapy Management (MTM) intervention
Trial: 11700852
Drug: Testosterone Enanthate
RxNorm normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone Enanthate (TE) 100 mg weekly
Trial: 11700852
Drug: Testosterone Enanthate
RxNorm normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone Enanthate (TE) 25 mg weekly
Trial: 11700852
Drug: Testosterone Enanthate
RxNorm normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone Enanthate (TE) 50 mg weekly
Trial: 11700852
Drug: Testosterone Enanthate
RxNorm normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone Enanthate (TE) 100 mg and 300 mg weekly
Trial: 9221556
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of TENS and tactile stimulation